Topigen is a privately-held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. Topigen’s pipeline included small molecule and RNA-based therapeutics. The Company’s Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with drugs, the Company expects to improve outcomes for many patients with respiratory diseases.
Topigen Secures US$6.0MM Financing From MMV Financial Inc.